Symbols

RNA

Avidity Biosciences·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RNA

Avidity Biosciences, Inc.

A biotech company developing oligonucleotide-based therapies for rare genetic disorders

Industry

Biological Technology

Established Date

11/13/2012

Listing Date

06/12/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

391

Fiscal Year Ends

12-31

Website

www.aviditybiosciences.com

Security Type

Common stock

Office address

10578 Science Center Drive, Suite 125, San Diego, CA 92121

Business

Introduction

Avidity Biosciences, Inc., was incorporated under the laws of the State of Delaware on November 13, 2012. The company is a biopharmaceutical company. The Company has pioneered a new class of oligonucleotide-based therapies, called antibody oligonucleotide conjugates (AOCs), designed to overcome the current limitations of oligonucleotide therapies to treat a variety of serious diseases. The company utilizes its proprietary AOC platform to design, plan and develop therapies that combine the precision of monoclonal antibodies (mAbs) with tissue-selective and oligonucleotide therapies to access previously unabsorbable tissue and cell types and more effectively target the underlying genetic drivers of the disease.

Company Financials

EPS

RNA has released its 2025 Q3 earnings. EPS was reported at -1.27, versus the expected -1.1, missing expectations. The chart below visualizes how RNA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RNA has released its 2025 Q3 earnings report, with revenue of 12.47M, reflecting a YoY change of 434.03%, and net profit of -174.44M, showing a YoY change of -116.97%. The Sankey diagram below clearly presents RNA's revenue sources and cost distribution.